<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714246</url>
  </required_header>
  <id_info>
    <org_study_id>PSU 26983</org_study_id>
    <nct_id>NCT00714246</nct_id>
  </id_info>
  <brief_title>Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study. The phase I portion of the study will determine the maximum&#xD;
      tolerated dose of bortezomib when administered in combination with carboplatin &amp; docetaxel&#xD;
      and to determine the efficacy of the combination for patients with advanced NSCLC. Phase II&#xD;
      will utilize the dosage determined in the Phase I and implement regimen to determine time to&#xD;
      progression, overall survival, and changes in serum proteomics patterns before &amp; after&#xD;
      combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A chemotherapy efficacy plateau' has been reached for the treatment of patients with advanced&#xD;
      or metastatic non-small cell lung cancer. Platinum-based two-drug combination is considered&#xD;
      the current standard of care for the treatment of advanced NSCLC. There is a need to develop&#xD;
      novel regimens to improve the outcome for patients with advanced NSCLC. The combination of&#xD;
      carboplatin and docetaxel is effective for therapy of advanced NSCLC. This combination&#xD;
      results in improved survival and quality of life for patients with advanced NSCLC. Docetaxel&#xD;
      exhibits preclinical synergy with bortezomib.&#xD;
&#xD;
      The trial was intended to be a phase I/II study to define the maximum tolerated dose of&#xD;
      bortezomib that can be administered in combination with docetaxel and carboplatin and&#xD;
      subsequently evaluate the efficacy of the regimen for patients with advanced NSCLC. However,&#xD;
      the trial never moved past the phase I portion of the study and was terminated early.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose of bortezomib when administered in combination with carboplatin &amp; docetaxel for treatment of patients with advanced NSCLC cancer. Determine the response rate of the combination for patients with advanced NSCLC.</measure>
    <time_frame>Expected average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define dose-limiting toxicities of the combination of carboplatin, docetaxel &amp; bortezomib for patients with advanced NSCLC. Determine the time to progression &amp; overall survival, assess toxicities, determine changes in serum proteomics patterns</measure>
    <time_frame>Expected average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>VELCADE</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or&#xD;
             stage IV NSCLC&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  ECOG PS &lt; 2&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated clinically active brain metastasis&#xD;
&#xD;
          -  Radiotherapy within 2 weeks prior to initiation of protocol therapy&#xD;
&#xD;
          -  Treatment with any investigational therapy within 4 weeks prior to enrollment&#xD;
&#xD;
          -  History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma&#xD;
             on situ of the cervix) within the last 5 years&#xD;
&#xD;
          -  Patients in their reproductive age group should use an effective method of birth&#xD;
             control. Men and women of childbearing potential must be willing to consent to using&#xD;
             effective contraception while on treatment and for at least 3 months thereafter.&#xD;
             Patients who are breast-feeding will be excluded from the study. Women of childbearing&#xD;
             potential must have a negative pregnancy test.&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to enrollment&#xD;
&#xD;
          -  Use of immunosuppressive agents including systemic corticosteroids within 4 weeks&#xD;
             prior to enrollment (corticosteroids are permitted as physiological replacement&#xD;
             therapy or as supportive care for nausea and emesis)&#xD;
&#xD;
          -  Known history of Human immunodeficiency virus infection&#xD;
&#xD;
          -  Any co-morbidity or condition of sufficient severity to limit full compliance with the&#xD;
             protocol per assessment by the investigator&#xD;
&#xD;
          -  Concurrent serious medical infection or illness, or psychiatric illness likely to&#xD;
             interfere with participation in this clinical study.&#xD;
&#xD;
          -  History of known hypersensitivity to docetaxel or other drugs formulated with&#xD;
             polysorbate 80, bortezomib, boron or mannitol&#xD;
&#xD;
          -  Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital&#xD;
             Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled&#xD;
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence&#xD;
             of acute ischemia or active conduction system abnormalities. Prior to study entry, any&#xD;
             ECG abnormality at Screening has to be documented by the investigator as not medically&#xD;
             relevant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandra P. Belani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Chandra P. Belani</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>advanced non small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

